Presented to CFSAC, December 13-14, 2017 by Courtney Miller, Board - PowerPoint PPT Presentation

Presented to CFSAC, December 13-14, 2017 by Courtney Miller, Board President

Simmaron Research: Goals • Redefine ME/CFS through science • Determine diagnostic markers • Identify scientific characteristics of subsets of ME/CFS patients • Pursue research that can lead to potential treatments • Harness the clinical experience of Dr. Peterson and his deep characterization of patients

Simmaron Accomplishments • Helped drive a strategic focus on immunological studies • 15 peer reviewed publications • Signature spinal fluid studies with published findings that reinforced immunological research • Collaborated in publishing subset findings: • Short duration v long duration • Classical v atypical cases • ME with and without Irritable Bowel Syndrome

NIH Center Grants: Pivotal & Promising

Patients & NIH Should be Proud • Largest infusion of NIH funding for ME/CFS in our collective memory - $35 million over 5 yrs • We praise patients and experts for bringing change to NIH • We praise NIH for doing the hard work to change its ME/CFS program, and we encourage more

Proud to Collaborate • Simmaron is collaborating in NIH Center grants: • Dr. Lipkin’s Center for Solutions to ME/CFS • Dr. Peterson is clinical collaborator • Deepens Simmaron’s 6-year partnership with Columbia Univ. • Study goals: assess immune functioning, metabolomics and microbiome, effect of exercise and stressors, and development of an app for patients to track disease details. • Dr. Maureen Hansen’s team at Cornell • Simmaron will provide samples

Upcoming Publications • Phase 2 of our spinal fluid studies should be ready for publication in the new year. • Looking forward to additional publications from the CDC Multi-site study • Believe that results need to be published to change the field

The Promise of Treatments • Treatment is the most pressing unmet need • We all have to build the field of evidence-based treatments collaboratively • Treatment trials are all but non-existent • The field needs to study responders to Ampligen, cidofovir, antivirals, rituximab, etc • Simmaron can do its part • Everyone on this committee has a part to do.

More information www.simmaronresearch.com Simmaron Research Inc. 948 Incline Way Incline Village, NV 89451